These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 12054148)
1. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Radbruch L; Sabatowski R; Petzke F; Brunsch-Radbruch A; Grond S; Lehmann KA Palliat Med; 2001 Jul; 15(4):309-21. PubMed ID: 12054148 [TBL] [Abstract][Full Text] [Related]
2. Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids. Mystakidou K; Befon S; Tsilika E; Dardoufas K; Georgaki S; Vlahos L Oncology; 2002; 62(1):9-16. PubMed ID: 11810038 [TBL] [Abstract][Full Text] [Related]
3. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Sittl R; Nuijten M; Nautrup BP Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481 [TBL] [Abstract][Full Text] [Related]
4. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Tawfik MO; Bryuzgin V; Kourteva G; Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835 [TBL] [Abstract][Full Text] [Related]
6. Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. Vielvoye-Kerkmeer AP; Mattern C; Uitendaal MP J Pain Symptom Manage; 2000 Mar; 19(3):185-92. PubMed ID: 10760623 [TBL] [Abstract][Full Text] [Related]
7. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers. Mystakidou K; Parpa E; Tsilika E; Katsouda E; Kouloulias V; Kouvaris J; Georgaki S; Vlahos L J Pain; 2004 Mar; 5(2):119-32. PubMed ID: 15042520 [TBL] [Abstract][Full Text] [Related]
8. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
9. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851 [TBL] [Abstract][Full Text] [Related]
10. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542 [TBL] [Abstract][Full Text] [Related]
11. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307 [TBL] [Abstract][Full Text] [Related]
12. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients. Griessinger N; Sittl R; Likar R Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522 [TBL] [Abstract][Full Text] [Related]
13. The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. Kang JH; Oh SY; Song SY; Lee HY; Kim JH; Lee KE; Lee HR; Hwang IG; Park SH; Kim WS; Park YS; Park K Korean J Intern Med; 2015 Jan; 30(1):88-95. PubMed ID: 25589840 [TBL] [Abstract][Full Text] [Related]
14. Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. Solassol I; Bressolle F; Caumette L; Garcia F; Poujol S; Culine S; Pinguet F Ther Drug Monit; 2005 Aug; 27(4):491-8. PubMed ID: 16044107 [TBL] [Abstract][Full Text] [Related]
15. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Ripamonti C; Fagnoni E; Campa T; Brunelli C; De Conno F Support Care Cancer; 2006 May; 14(5):400-7. PubMed ID: 16485087 [TBL] [Abstract][Full Text] [Related]
16. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study. Clemens KE; Klaschik E Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302 [TBL] [Abstract][Full Text] [Related]
17. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504 [TBL] [Abstract][Full Text] [Related]
18. Fentanyl transdermal system. Pain management at home. Woodroffe MA; Hays H Can Fam Physician; 1997 Feb; 43():268-72. PubMed ID: 9040914 [TBL] [Abstract][Full Text] [Related]
19. Utilisation of transdermal fentanyl in Germany from 2004 to 2006. Garbe E; Jobski K; Schmid U Pharmacoepidemiol Drug Saf; 2012 Feb; 21(2):191-8. PubMed ID: 21681850 [TBL] [Abstract][Full Text] [Related]
20. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. Mitra F; Chowdhury S; Shelley M; Williams G Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]